CCR4

Le CCR4, ou CD194 est un récepteur aux chémokines CC avec également un rôle de cluster de différenciation. Son gène est le CCR4 porté par le chromosome 3 humain.

Rôles

Il est exprimé préférentiellement à la surface des lymphocyte T auxiliaires de type 2 (Th2)^[1], essentiellement au niveau de la peau^[2]. Ses ligands sont le CCL17 et le CCL22^[3].

En médecine

Il est exprimé à la surface des cellules lymphocytaires situés dans les infiltrats de plusieurs cancers, dont le glioblastomes^[3], le cancer du sein^[4]. Il semble être un indicateur de mauvais pronostic sur ce dernier^[5]. Il est exprimé également dans les cellules du cancer de l'estomac, constituant un marqueur pronostic^[6].

Un anticorps monoclonal ciblant cette protéine, le mogamulizumab , est en cours de test dans les lymphomes^[7].

Notes et références

↑ Bonecchi R, Bianchi G, Bordignon PP et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s, J Exp Med, 1998;187:129–134
↑ Kunkel EJ, Boisvert J, Murphy K et al. Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes, Am J Pathol, 2002;160:347–355
↑ ^{a et b} Yoshie O, Matsushima K, CCR4 and its ligands: from bench to bedside, Int Immunol, 2015;27:11–20
↑ Gobert M, Treilleux I, Bendriss-Vermare N et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome, Cancer Res, 2009;69:2000–2009
↑ Li JY, Ou ZL, Yu SJ et al. The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer, Breast Cancer Res Treat, 2012;131:837–848
↑ Lee JH, Cho YS, Lee JY, Kook MC, Park JW, Nam BH, Bae JM, The chemokine receptor CCR4 is expressed and associated with a poor prognosis in patients with gastric cancer, Ann Surg, 2009;249:933–941
↑ Ogura M, Ishida T, Hatake K et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma, J Clin Oncol, 2014;32:1157–1163

[Bonecchi_1998-1] Bonecchi R, Bianchi G, Bordignon PP et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s, J Exp Med, 1998;187:129–134

[Kunkel_2002-2] Kunkel EJ, Boisvert J, Murphy K et al. Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes, Am J Pathol, 2002;160:347–355

[Yoshie_2015-3] {a et b} Yoshie O, Matsushima K, CCR4 and its ligands: from bench to bedside, Int Immunol, 2015;27:11–20

[Gobert_2009-4] Gobert M, Treilleux I, Bendriss-Vermare N et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome, Cancer Res, 2009;69:2000–2009

[Li_2012-5] Li JY, Ou ZL, Yu SJ et al. The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer, Breast Cancer Res Treat, 2012;131:837–848

[Lee_2009-6] Lee JH, Cho YS, Lee JY, Kook MC, Park JW, Nam BH, Bae JM, The chemokine receptor CCR4 is expressed and associated with a poor prognosis in patients with gastric cancer, Ann Surg, 2009;249:933–941

[Ogura_2014-7] Ogura M, Ishida T, Hatake K et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma, J Clin Oncol, 2014;32:1157–1163

[1]

[2]

[3]

[4]

[5]

[6]

[7]